The global pharmaceutical industry is expected to generate sales of over $1.2 trillion by 2025, with the oncology segment contributing significantly, projected to reach $208 billion next year. This growth is supported by an annual increase of 4.7%, potentially reaching total sales of $1.45 trillion by 2029.

Pharmaceutical Stocks as Attractive Options

In the current economic landscape, pharmaceutical stocks are becoming attractive options for investors seeking defensive assets. Several pharmaceutical stocks with dividend yields of at least 2% are worth considering for reliable income sources. These include Johnson & Johnson (JNJ), Merck & Co. Inc. (MRK), Amgen Inc. (AMGN), Sanofi (SNY), Gilead Sciences Inc. (GILD), GSK PLC (GSK), and Perrigo Co. PLC (PRGO). Each of these companies not only offers dividends but also presents significant upside potential for long-term investors.

Johnson & Johnson: A Global Leader

Johnson & Johnson is a global leader in pharmaceuticals, medical devices, and consumer health care products. With a diverse portfolio that includes Stelara and Tylenol, the company is well-positioned for future growth.

Merck & Co. Inc.: Revenue Growth and Regulatory Approvals

Merck & Co. Inc. reported a 7% revenue growth in the second quarter, driven by sales from its leading cancer drug, Keytruda. The company consistently gains regulatory approvals for new drugs, enhancing its growth prospects.

Amgen Inc.: Positive Developments and FDA Approvals

Amgen Inc., one of the largest biotechnology firms globally, has seen positive developments, including FDA approvals for new treatments.

Sanofi: Specializing in Atopic Allergic Disorders and Oncology

Sanofi specializes in treating atopic allergic disorders and oncology, with a diverse portfolio that includes diabetes treatments.

Gilead Sciences Inc.: Focus on HIV/AIDS and Oncology

Gilead Sciences Inc. focuses on developing treatments for HIV/AIDS and oncology, with leading drugs like Biktarvy and Veklury.

Perrigo Co. PLC: Shifting Focus to Self-Care Products

Perrigo Co. PLC has shifted its focus to self-care products, recently gaining FDA approval for the first over-the-counter daily oral contraceptive pill in the U.S.

GSK PLC: Diverse Product Lineup and Specialty Medicine Segment

GSK PLC has a diverse product lineup that includes asthma and cold medications, with significant revenue contributions from its specialty medicine segment.

In conclusion, the pharmaceutical sector offers stability and income generation through dividends. With a mix of established giants and emerging players, investors have a range of options to consider for both income and capital appreciation.